Antibody-drug conjugates in patients with advanced/metastatic HER2-low-expressing breast cancer: a systematic review and meta-analysis.

ABSTRACT:

Background

Until recently, targeted therapies have failed to benefit patients with human epidermal growth factor receptor 2 (HER2)-low-expressing breast cancer (BC). Nevertheless, antibody-drug conjugates (ADCs) have reshaped their prognosis.

Objectives

We performed a systematic review and meta-analysis to assess the effectiveness of ADCs in patients with HER2-low advanced/metastatic (a/m) BC.

Design

This study is a systematic review and meta-analysis.

Data sources

We searched PubMed, Embase, and Cochrane databases as well as the American Society of Clinical Oncology, European Society for Medical Oncology, and San Antonio Breast Cancer Symposium conference proceedings.

Methods

Studies evaluating ADCs (trastuzumab deruxtecan (T-DXd), sacituzumab govitecan

SUBMITTER: Michelon I 

PROVIDER: S-EPMC11580099 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature